Cancer incidence and mortality in France over the period 1978-2000, Rev Epiderniol Sante Publique, vol.5, issue.1, pp.3-30, 2003. ,
URL : https://hal.archives-ouvertes.fr/hal-00427472
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer, New England Journal of Medicine, vol.353, issue.25, pp.2654-66, 2005. ,
DOI : 10.1056/NEJMoa051424
Microsattelite instability accounts for tumor site related differences in clinicopathologic variable and prognosis in human colon cancers, Am J, vol.101, issue.1 2, pp.28-46, 2006. ,
A phase III study of irinotecan (CPT-1 1) versus best supportive care in patients with metastatic colorectal cancer who have failed 5- fluorouracil therapy. V301 Study Group, Semin Oncol, vol.26, issue.1, pp.6-12, 1999. ,
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines, Annals of Oncology, vol.7, issue.1, pp.95-103, 1996. ,
DOI : 10.1093/oxfordjournals.annonc.a010489
FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study, Journal of Clinical Oncology, vol.22, issue.2, pp.229-237, 2004. ,
DOI : 10.1200/JCO.2004.05.113
Irinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer, New England Journal of Medicine, vol.343, issue.13, pp.905-914, 2000. ,
DOI : 10.1056/NEJM200009283431302
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial, The Lancet, vol.355, issue.9209, pp.1041-1047, 2000. ,
DOI : 10.1016/S0140-6736(00)02034-1
Irinotecan mechanisms of tumor resistance and novels startegies for modulating its activity, Ann of Oncol, vol.13, pp.184-185, 2002. ,
A Simple Method for the Routine Detection of Somatic Quantitative Genetic Alterations in Colorectal Cancer, Gastroenterology, vol.132, issue.2, pp.645-53, 2007. ,
DOI : 10.1053/j.gastro.2006.12.006
Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995. ,
DOI : 10.1016/1040-8428(94)00144-I
IMC- C225) plus irinotecan (CPT-11) is active in CPT-1 1-refractory colorectal cancer that expresses epidermal growth factor receptor, 2001. ,
Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor, Journal of Clinical Oncology, vol.22, issue.7, pp.1201-1209, 2004. ,
DOI : 10.1200/JCO.2004.10.182
Essai de phase II randomisé, cétuximab en association avce l'irinotécan ou en monothérapie chez des patients ayant progressés sous irinotécan et exprimant le récepteur de 17Epidermal Growth Factor, 2004. ,
Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal Cancer, New England Journal of Medicine, vol.351, issue.4, pp.337-345, 2004. ,
DOI : 10.1056/NEJMoa033025
Targetting the epidermal growth factor receptor in colorectal cancer: clinical results, Bull Cancer, vol.92, pp.21-29, 2005. ,
Cutaneous side-effects of kinase inhibitors and blocking antibodies, The Lancet Oncology, vol.6, issue.7, pp.491-500, 2005. ,
DOI : 10.1016/S1470-2045(05)70243-6
Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer, Anti-Cancer Drugs, vol.17, issue.7, pp.855-857, 2006. ,
DOI : 10.1097/01.cad.0000217425.44584.9f
EGF, TGF-a, and EGF-R in Human Colorectal Adenocarcinoma, Acta Oncologica, vol.88, issue.3, pp.285-294, 1998. ,
DOI : 10.1038/bjc.1992.39
Epidermal growth factor-related peptides and their receptors in human malignancies, Critical Reviews in Oncology/Hematology, vol.19, issue.3, pp.183-232, 1995. ,
DOI : 10.1016/1040-8428(94)00144-I
Cetuximab Shows Activity in Colorectal Cancer Patients With Tumors That Do Not Express the Epidermal Growth Factor Receptor by Immunohistochemistry, Journal of Clinical Oncology, vol.23, issue.9, pp.1803-1821, 2005. ,
DOI : 10.1200/JCO.2005.08.037
Epidermal Growth Factor Receptor (EGFR) Status in Primary Colorectal Tumors Does Not Correlate With EGFR Expression in Related Metastatic Sites: Implications for Treatment With EGFR-Targeted Monoclonal Antibodies, Journal of Clinical Oncology, vol.22, issue.23 ,
DOI : 10.1200/JCO.2004.00.117
Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study, The Lancet Oncology, vol.6, issue.5, pp.279-286, 2005. ,
DOI : 10.1016/S1470-2045(05)70102-9
Immunohistochernical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choise of fixative and storage time of tissue sections, J Histochem, vol.52, pp.893-901, 2004. ,
Protein overexpression and gene amplification of HER-2 and EGFR in colorectal cancers: an immunohistochemical and fluorescent in situ hybridization study, Modern Pathology, vol.18, issue.8, pp.895-904, 2004. ,
DOI : 10.1200/JCO.2000.18.4.904
Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer, Cancer Research, vol.66, issue.8, pp.3992-3995, 2006. ,
DOI : 10.1158/0008-5472.CAN-06-0191
Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy, British Journal of Cancer, vol.14, issue.8, pp.1-166, 2007. ,
DOI : 10.1093/jnci/92.3.205
Molecular Determinants of Cetuximab Efficacy, Journal of Clinical Oncology, vol.23, issue.15, pp.3536-3544, 2005. ,
DOI : 10.1200/JCO.2005.09.100
New Guidelines to Evaluate the Response to Treatment in Solid Tumors, JNCI: Journal of the National Cancer Institute, vol.92, issue.3, pp.205-216, 2000. ,
DOI : 10.1093/jnci/91.6.523
Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines, Journal of Clinical Oncology, vol.24, issue.30, pp.4914-4921, 2006. ,
DOI : 10.1200/JCO.2006.06.7595
Cetuximab and irinotecan as third-line therapy in advanced colorectal cancer patients: a single centre phase II trial, British Journal of Cancer, vol.10, issue.6, pp.94-792, 2006. ,
DOI : 10.1634/theoncologist.10-4-250
Quality of life in patients with advanced colorectal cancer, European Journal of Cancer, vol.39, issue.3, pp.287-94, 2003. ,
DOI : 10.1016/S0959-8049(02)00664-0
Options et Recommandations; Institut national du cancer; Federation nationale des centres de lutte contre le cancer; Ligue nationale contre le cancer; Société nationale francaise de Castro-Enterologie; FFCD; GERCOR; Federation hospitalière de France; Federation nationale de Cancerologie des CHRU; Federation francaise de cancérologie des CHG. Recommendations for clinical practice: management with first-line palliative chemotherapy for patients with metastatic colorectalcancer Bull Cancer, Feb, vol.1, issue.932, pp.197-200, 2006. ,
Age as a prognosis factor in colorectal cancer treatment, Przegl Lek, vol.62, issue.12, pp.1440-1443, 2005. ,
Rectal Cancer in the Young Patient, Diseases of the Colon & Rectum, vol.49, issue.7, pp.993-1001, 2006. ,
DOI : 10.1007/s10350-006-0558-6
Clinical determinants of survival in patients with 5-fluorouracil- based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients, Annals of Oncology, vol.13, issue.2, pp.308-311, 2002. ,
DOI : 10.1200/JCO.1999.17.5.1364
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials, Annals of Oncology, vol.15, issue.7, pp.1013-1017, 2004. ,
DOI : 10.1093/annonc/mdh267
A clinical nomogram for predicting long-term survival in advanced colorectal cancer, European Journal of Cancer, vol.36, issue.16, pp.2044-2052, 2000. ,
DOI : 10.1016/S0959-8049(00)00286-0
Epidermal growth factor is increased in multidsug-resistan Chinese hamster and mouse tumor cells ,
Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-1 1) against human colorectal tumor xenografts, Clin Cancer Res, vol.8, pp.994-1003, 2002. ,
Irinotecan Hydrochloride (CPT-11) Resistance Identified by K-ras Mutation in Patients with Progressive Colon Cancer After Treatment with 5-Fluorouracil (5-FU), American Journal of Clinical Oncology, vol.20, issue.5, pp.527-529, 1997. ,
DOI : 10.1097/00000421-199710000-00020
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma, Gut, vol.54, issue.9, pp.1283-1286, 2005. ,
DOI : 10.1136/gut.2005.066514
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype, Annals of Oncology, vol.13, issue.9, pp.1438-1446, 2002. ,
DOI : 10.1093/annonc/mdf226
Systematic review of genetic influences on the prognosis of colorectal cancer, British Journal of Surgery, vol.91, issue.10, pp.1275-129, 2004. ,
DOI : 10.1002/bjs.4737
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma, British Journal of Cancer, vol.82, issue.11-12, pp.1800-1805, 1999. ,
DOI : 10.1002/(SICI)1097-0142(19980501)82:9<1626::AID-CNCR5>3.0.CO;2-8
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer, The Lancet, vol.352, issue.9138, pp.1413-1421, 1998. ,
DOI : 10.1016/S0140-6736(98)02309-5
Ki-ras mutations and prognosis in colorectal cancer, Eur J Cancer, vol.34, issue.4, pp.5-18, 1998. ,